CCR1 inhibitor 19e, identified by its CAS number 1220026-26-5, is a chemical compound that functions as an antagonist of the CCR1 receptor, which is part of the chemokine receptor family involved in immune responses and inflammatory processes. This compound is characterized by its ability to selectively inhibit the CCR1 receptor, thereby potentially modulating various biological pathways associated with inflammation and immune cell trafficking. The structure of CCR1 inhibitor 19e typically includes specific functional groups that enhance its binding affinity and selectivity for the CCR1 receptor. Its pharmacological profile suggests potential therapeutic applications in conditions where CCR1 is implicated, such as autoimmune diseases and chronic inflammatory disorders. Additionally, the compound's efficacy and safety profile would be evaluated through preclinical and clinical studies to determine its viability as a therapeutic agent. As with many small molecule inhibitors, understanding its solubility, stability, and metabolic pathways is crucial for its development and application in medicinal chemistry.

CCR1 inhibitor 19e

1220026-26-5: CCR1 inhibitor 19e, identified by its CAS number 1220026-26-5, is a chemical compound that functions as an antagonist of the CCR1 receptor, which is part of the chemokine receptor family involved in immune responses and inflammatory processes. This compound is characterized by its ability to selectively inhibit the CCR1 receptor, thereby potentially modulating various biological pathways associated with inflammation and immune cell trafficking. The structure of CCR1 inhibitor 19e typically includes specific functional groups that enhance its binding affinity and selectivity for the CCR1 receptor. Its pharmacological profile suggests potential therapeutic applications in conditions where CCR1 is implicated, such as autoimmune diseases and chronic inflammatory disorders. Additionally, the compound's efficacy and safety profile would be evaluated through preclinical and clinical studies to determine its viability as a therapeutic agent. As with many small molecule inhibitors, understanding its solubility, stability, and metabolic pathways is crucial for its development and application in medicinal chemistry.

<p>CCR1 antagonist 9 (compound 19e) is a selective CCR1 antagonist based on aziridine. CCR1 inhibition in calcium flux assays.</p>

CAS 1220026-26-5

CCR1 inhibitor 19e

CCR1 antagonist 9

Ref: TM-T10710